This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LabCorp (LH) Partners HealthVerity to Grow in Drug Development
by Zacks Equity Research
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $290.90, marking a +0.98% move from the previous day.
LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test
by Zacks Equity Research
LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.
The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna
by Zacks Equity Research
Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.
Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More
by Kinjel Shah
FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
by Kinjel Shah
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.
Eli Lilly (LLY) Stock Moves -1.93%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $291.28, moving -1.93% from the previous trading session.
Is Invesco Dynamic Large Cap Growth ETF (PWB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWB
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
by Zacks Equity Research
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $313.49 in the latest trading session, marking a +0.45% move from the prior day.
Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year
by Zacks Equity Research
Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.
Company News for Jun 7, 2022
by Zacks Equity Research
Companies in The News Are: SIAC,LLY,SEDG,SAVE,JBLU
LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program
by Zacks Equity Research
LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.
Radius (RDUS) to Stop Work on Abaloparatide Transdermal System
by Zacks Equity Research
Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.
Pfizer (PFE) Up 5.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Eli Lilly, ConocoPhillips, PNC Financial Services, Equinix, and Freeport-McMoRan
by Zacks Equity Research
Eli Lilly, ConocoPhillips, PNC Financial Services, Equinix, and Freeport-McMoRan are part of Zacks top Analyst Blog.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Top Stock Reports for Eli Lilly, ConocoPhillips & PNC Financial
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), ConocoPhillips (COP), and The PNC Financial Services Group, Inc. (PNC).
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
by Zacks Equity Research
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata
by Zacks Equity Research
The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.
Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug
by Zacks Equity Research
Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide
by Kinjel Shah
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FVD